Vistica DT - Search Results

1

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT. Loaiza-Pérez AI, et al. Among authors: vistica dt. J Urol. 2004 Apr;171(4):1688-97. doi: 10.1097/01.ju.0000108860.03389.1b. J Urol. 2004. PMID: 15017268

2

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA. Loaiza-Pérez AI, et al. Among authors: vistica dt. Mol Cancer Ther. 2004 Jun;3(6):715-25. Mol Cancer Ther. 2004. PMID: 15210858

3

Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism.

Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA. Rivera MI, et al. Among authors: vistica dt. Biochem Pharmacol. 1999 Jun 1;57(11):1283-95. doi: 10.1016/s0006-2952(99)00046-5. Biochem Pharmacol. 1999. PMID: 10230772

4

Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.

Kamishohara M, Kenney S, Domergue R, Vistica DT, Sausville EA. Kamishohara M, et al. Among authors: vistica dt. Exp Cell Res. 2000 May 1;256(2):468-79. doi: 10.1006/excr.2000.4851. Exp Cell Res. 2000. PMID: 10772819

5

Role of membrane potential in the accumulation of quaternized ellipticines by human tumor cell lines.

Vistica DT, Kenney S, Hursey M, Boyd MR. Vistica DT, et al. J Pharmacol Exp Ther. 1996 Nov;279(2):1018-25. J Pharmacol Exp Ther. 1996. PMID: 8930212

6

ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.

Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH. Kenney S, et al. Among authors: vistica dt. J Pediatr Hematol Oncol. 2011 Jul;33(5):360-8. doi: 10.1097/MPH.0b013e3182002f9f. J Pediatr Hematol Oncol. 2011. PMID: 21552147 Free PMC article.

7

Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH. Vistica DT, et al. J Pediatr Hematol Oncol. 2009 Aug;31(8):561-70. doi: 10.1097/MPH.0b013e3181a6e043. J Pediatr Hematol Oncol. 2009. PMID: 19636271 Free PMC article.

8

Uptake and cytotoxicity of 9-methoxy-N2-methylellipticinium acetate in human brain and non-brain tumor cell lines.

Kenney S, Vistica DT, Linden H, Boyd MR. Kenney S, et al. Among authors: vistica dt. Biochem Pharmacol. 1995 Jan 6;49(1):23-32. doi: 10.1016/0006-2952(94)00471-w. Biochem Pharmacol. 1995. PMID: 7840779

9

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. Monks A, et al. J Natl Cancer Inst. 1991 Jun 5;83(11):757-66. doi: 10.1093/jnci/83.11.757. J Natl Cancer Inst. 1991. PMID: 2041050

10

New colorimetric cytotoxicity assay for anticancer-drug screening.

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. Skehan P, et al. J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12. doi: 10.1093/jnci/82.13.1107. J Natl Cancer Inst. 1990. PMID: 2359136

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page